ARWR · Company research
Arrowhead Research Corporation (ARWR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform (NASDAQ:ARWR) - Seeking Alpha | Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform (NASDAQ:ARWR) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Stocktwits | ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval Stocktwits | View source ↗ | Stocktwits | Oct 15, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance | Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline - Slideshow (NASDAQ:ARWR) 2026-10-14 - Seeking Alpha | Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline - Slideshow (NASDAQ:ARWR) 2026-10-14 Seeking Alpha | View source ↗ | Seeking Alpha | Oct 14, 2026 | neutral | 0 | 0.6 |
| Arrowhead stock gains on trial data for Alzheimer’s drug (ARWR) - Seeking Alpha | Arrowhead stock gains on trial data for Alzheimer’s drug (ARWR) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 14, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News, Quote & History - Yahoo! Finance Canada | Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance | Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| A planned drug filing for very high blood fats qualifies for a six-month FDA review - Stock Titan | A planned drug filing for very high blood fats qualifies for a six-month FDA review Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Stock Forecast & Analyst Predictions - Simply Wall Street | Arrowhead Pharmaceuticals (NasdaqGS:ARWR) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo Finance Singapore | Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 7, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher - Seeking Alpha | Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher Seeking Alpha | View source ↗ | Seeking Alpha | Oct 3, 2026 | neutral | 0 | 0.6 |
| Is Arrowhead Pharmaceuticals (ARWR) Stock Still Reasonable After Trial Results? - Webull | Is Arrowhead Pharmaceuticals (ARWR) Stock Still Reasonable After Trial Results? Webull | View source ↗ | Webull | Oct 1, 2026 | neutral | 0 | 0.6 |
| Is Arrowhead Pharmaceuticals (ARWR) Stock Still Reasonable After Trial Results? - Simply Wall Street | Is Arrowhead Pharmaceuticals (ARWR) Stock Still Reasonable After Trial Results? Simply Wall Street | View source ↗ | Simply Wall Street | Sep 29, 2026 | neutral | 0 | 0.6 |
| Interim results from an experimental Alzheimer’s drug study will be presented Oct. 14. - Stock Titan | Interim results from an experimental Alzheimer’s drug study will be presented Oct. 14. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near - TradingView | ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near TradingView | View source ↗ | TradingView | Sep 24, 2026 | neutral | 0 | 0.6 |
| ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near - Stocktwits | ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near Stocktwits | View source ↗ | Stocktwits | Sep 24, 2026 | neutral | 0 | 0.6 |
| $ARWR stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $ARWR stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 15, 2026 | neutral | 0 | 0.6 |
| Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - Yahoo Finance | Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 28, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress - Simply Wall Street | Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress Simply Wall Street | View source ↗ | Simply Wall Street | Aug 6, 2026 | neutral | 0 | 0.6 |
| ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits | ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data Stocktwits | View source ↗ | Stocktwits | Jul 22, 2026 | neutral | 0 | 0.6 |
| Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run - Yahoo Finance | Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run Yahoo Finance | View source ↗ | Yahoo Finance | Jul 22, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.